Kane Biotech Inc. (KNE.V)
| Previous Close | 0.1150 |
| Open | 0.1200 |
| Bid | 0.1150 x 0 |
| Ask | 0.1200 x 0 |
| Day's Range | 0.1150 - 0.1200 |
| 52 Week Range | 0.0800 - 0.1400 |
| Volume | |
| Avg. Volume | 30,701 |
| Market Cap | 14.355M |
| Beta (5Y Monthly) | 0.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0420 |
| Earnings Date | Mar 22, 2023 - Mar 27, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Kane Biotech Announces Extension of Term of Credit Facility
Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”) announces today that it has entered into an amending agreement with Pivot Financial I Limited Partnership (“Pivot”) to the amended and restated credit agreement between the Company and Pivot dated August 31, 2021, extending the maturity date of its credit facility from January 31, 2023 to Februa
- GlobeNewswire
Kane Biotech Announces First Distribution Agreement for its coactiv+™ Antimicrobial Hydrogel
Salud Pharma to launch product in Colombia, Panama, and Costa RicaWINNIPEG, Manitoba, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces today that it has recently signed a distribution agreement with Salud Pharma S.A. (“Salud Pharma”) for its coactiv+™ Antimicrobial Hydrogel wound care and DermaKB™ scalp care products. Once Kane obtains 510(k) approval from the FDA, Salud Pharma through its distribution partners will register
